







an Open Access Journal by MDPI

# **Analysis of Cancer Radiotherapy**

Guest Editor:

Prof. Dr. Michael L. F. Lerch

Centre for Medical Radiation Physics, School of Physics, University of Wollongong, Wollongong, Australia

Deadline for manuscript submissions:

closed (31 December 2022)

## Message from the Guest Editor

Dear Colleagues,

This Special Issue will focus on highlighting the latest developments in emerging and established cancer radiation treatments (photon and particle based) that are relevant to the global research and clinical communities. The scope of the Special Issue will include significant technical advances, new theranostic platforms and multimodal treatment options for improving cancer radiation treatments and quality assurance with a view to demonstrating improved treatment efficacy via in vitro or in vivo datasets or clinical trial cohorts.

Dr. Michael Lerch













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**